| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
NUPR1 (IC50 = 0.42 μM); NUPR1 (IC50 = 7.75 μM)
|
|---|---|
| ln Vitro |
ZZW-115 is capable of efficiently killing the pancreatic tumor cell lines by targeting NUPR1 and inhibits the growth of other tumor-derived cells. ZZW-115 causes a temporary metabolic shift toward anaerobic glycolysis inhibition, which leads to a decrease in ATP production by the mitochondria, as well as an increase in mitochondrial ROS production. [1]
|
| ln Vivo |
ZZW-115 can disrupt tumor growth at low doses and can reduce tumor size for the xenografted tumors, without obvious neurological side effects in the mice. ZZW-115 is a very effective anticancer drug candidate in vivo on mice because, primarily through necrosis, it is capable of not only halting tumor growth but also of reducing tumor size until its disappearance. [1]
|
| Cell Assay |
In 96-well plates, cells are plated. After 24 hours, the media are supplemented with ZZW-115 at a concentration of 0-100 μM, and they are incubated for a further 24 or 72 hours. According to the supplier's protocol, cell viability is calculated 3 hours after adding the CellTiter-Blue viability reagent (Promega). Concerns about cell viability improved in comparison to untreated cell rates.
|
| Animal Protocol |
NMRI-Foxn1nu/Foxn1nu mice (nude mice) xenografted with MiaPaCa-2 cells[1]
5, 2.5, 1.0, or 0.5 mg/kg Injection; daily for 30 days |
| References |
| Molecular Formula |
C24H34CL3F3N4S
|
|---|---|
| Exact Mass |
572.152
|
| Elemental Analysis |
C, 50.22; H, 5.97; Cl, 18.53; F, 9.93; N, 9.76; S, 5.59
|
| CAS # |
10122-45-9
|
| Related CAS # |
ZZW-115;801991-87-7
|
| PubChem CID |
154573789
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
582
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OBSKIDNFCBBXKJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H31F3N4S.3ClH/c1-28(2)12-13-30-16-14-29(15-17-30)10-5-11-31-20-6-3-4-7-22(20)32-23-9-8-19(18-21(23)31)24(25,26)27;;;/h3-4,6-9,18H,5,10-17H2,1-2H3;3*1H
|
| Chemical Name |
N,N-dimethyl-2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanamine;trihydrochloride
|
| Synonyms |
ZZW-115 hydrochloride; ZZW 115 HCl; ZZW-115 HCl; ZZW115 HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 83.3~93 mg/mL (145.2~162.0 mM)
Water: ~46 mg/mL (~80.1 mM) Ethanol: ~2 mg/mL (~3.5 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (10.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (10.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 50 mg/mL (87.11 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
